ArticleMycopathologia2026
Timing of Antifungal Treatment and Prognostic Factors in Talaromyces marneffei Infection: A Retrospective Analysis of HIV-Positive Cases.
Article in Mycopathologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionTalaromyces marneffei (TM) infection is an emerging global threat that increasingly affects immunocompromised individuals, including those with HIV/AIDS. This study aims to systematically analyze the clinical characteristics and treatment regimens of TM infection in HIV-positive patients, with a focus on exploring the optimal timing for antifungal therapy.
designA retrospective cross-sectional analysis was performed on 96 HIV-positive patients with TM infection from the Fourth People's Hospital of Nanning, Guangxi. The analysis included symptom manifestations, symptom combination patterns, laboratory test results, co-infection status, complications, and a comprehensive evaluation of treatment regimens, including medication types, combination strategies, and timing of administration.
resultsThe study divided patients into three groups: rapid progression death group, stable progression death group, and survival group, to dissect the heterogeneity of the disease (the first two groups collectively constitute the Death Group, representing all deceased patients). Through statistical modeling and visual data exploration, a critical value of one month for medication timing was determined. Further multivariate analysis revealed that medication timing exceeding one month was identified as an independent risk factor for patient mortality. Renal impairment and serum albumin levels < 30 g/dL were identified as poor prognostic factors, while fever and hepatosplenomegaly were associated with a better prognosis, reflecting the body's immune response capacity.
conclusionsThe conclusions of this study provide empirical evidence for early empirical treatment of TM infection, explicitly defining the critical therapeutic time window as within 1 month of symptom onset. This information is crucial for improving patient outcomes and managing TM infection in immunocompromised populations.
Indexed as
Identifiers
41572032What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.